Clinical Trials

8 enrolled

Prostatic Neoplasms

NCT02465060 2026-04-13

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

6,452 enrolled 2 FDA

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT04550494 2026-04-13

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

BreastGastrointestinalGenitourinaryGynecologic

36 enrolled

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT06616155 2026-04-13

Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Recruiting

39 enrolled

Phase NA Not yet recruiting

Prostatic Neoplasms

NCT07526545 2026-04-13

UPRISE

800 enrolled

Prostatic Neoplasms

NCT07145177 2026-03-23

177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer

30 enrolled

Phase NA Not yet recruiting

Prostatic Neoplasms

NCT07468903 2026-03-19

Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer

45 enrolled

Prostatic Neoplasms

NCT05435495 2026-03-18

Mechanisms of Resistance to PSMA Radioligand Therapy

Recruiting

125 enrolled

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT03317392 2026-02-19

Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis

145 enrolled

Prostatic Neoplasms

NCT04947254 2026-02-19

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

200 enrolled

Prostatic Neoplasms

NCT06305598 2026-02-19

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

14 enrolled

Prostatic Neoplasms

NCT06236139 2026-02-17

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Recruiting

48 enrolled

Prostatic Neoplasms

NCT04754425 2026-02-06

Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer

Phase 2 Terminated

11 enrolled

Prostatic Neoplasms

NCT05730712 2026-02-06

Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer

Phase 2 Completed

7 enrolled

Prostatic Neoplasms

NCT02312401 2026-01-29

Evaluation of Treatment Response Using Multiparametric MRI After Prostate Radiotherapy

120 enrolled

Prostatic Neoplasms

NCT06145633 2026-01-28

Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

15 enrolled

Prostatic Neoplasms

NCT07352748 2026-01-28

MOSAIC

Active not recruiting

30 enrolled

Prostatic Neoplasms

NCT06039371 2026-01-14

Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

69 enrolled

Prostatic Neoplasms

NCT06391034 2026-01-07

Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer

161 enrolled

Prostatic Neoplasms

NCT06630325 2026-01-07

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

GastrointestinalGenitourinaryGynecologic

30 enrolled

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT05805371 2025-11-19

PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer

21 enrolled

Prostatic Neoplasms

NCT05362032 2025-10-24

Feasibility of OmnEcoil System for Integrated Endorectal MRI and Transrectal MRI-Targeted Biopsy of the Prostate

Phase NA Suspended

45 enrolled

Prostatic Neoplasms

NCT06528210 2025-09-23

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer

Phase 2 Withdrawn

Prostatic Neoplasms

NCT05438563 2025-09-09

MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Low to Intermediate Grade Prostate Cancer

Phase NA Recruiting

100 enrolled

Prostatic Neoplasms

NCT06424275 2025-08-15

PRAISE-U

Enrolling by invitation

20,000 enrolled

Prostatic Neoplasms

NCT02769962 2025-07-28

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

Phase 1/2 Completed

45 enrolled 30 charts

GenitourinaryThoracic

Carcinoma, Transitional Cell, Lung Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT02543905 2025-07-25

PROFILE

Recruiting

1,600 enrolled

Prostatic Neoplasms

NCT06942104 2025-07-18

Imaging of Solid Tumors Using 18F-TRX

56 enrolled

CNSGenitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell, Glioma, Neoplasm Metastasis, Prostatic Neoplasms

NCT05304858 2025-04-25

Tumor Microenvironment Analysis of Prostate Cancer Metastasis

Recruiting

16 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT06094842 2025-04-01

Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer

Phase 1 Withdrawn

Prostatic Neoplasms

NCT05228197 2025-01-22

IP6-CHAIROS

Active not recruiting

750 enrolled

Prostatic Neoplasms

NCT05655715 2024-10-16

CheckPRO

Phase 2 Completed

90 enrolled

Neoplasms, Prostatic Neoplasms

NCT02933255 2024-05-31

PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer

Phase 1/2 Completed

24 enrolled 20 charts

Prostatic Neoplasms

NCT02555189 2024-05-13

Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression

Phase 1/2 Completed

46 enrolled

Prostatic Neoplasms

NCT05807126 2024-05-02

Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

Phase 1 Withdrawn

Phase EARLY_PHASE1 Withdrawn

Prostatic Neoplasms

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT03225222 2023-09-07

MR-PROPER

2,558 enrolled

Prostatic Neoplasms

NCT00499174 2023-08-23

Observation or Radical Treatment in Patients With Prostate Cancer

Phase NA Terminated

180 enrolled 9 charts

Prostatic Neoplasms

NCT05069584 2023-05-23

PERFECT

Phase NA Completed

270 enrolled

Prostatic Neoplasms

NCT05603351 2022-11-02

ProstaPilot

Phase NA Unknown

300 enrolled

Prostatic Neoplasms

NCT04247217 2022-05-26

PRIMUS

10 enrolled

Prostatic Neoplasms

NCT04746300 2021-02-09

PROMPT

Unknown

400 enrolled

Prostatic Neoplasms

NCT02229565 2020-11-13

GENCADE

226 enrolled

Prostatic Neoplasms

NCT00458549 2018-07-13

Polyunsaturated Fatty Acids in Treating Patients With Prostate Cancer Undergoing Prostate Biopsy and/or Surgery

Phase NA Terminated

232 enrolled

Prostatic Neoplasms

NCT00996749 2018-07-03

Omega-3 Fatty Acids in Treating Patients With Advanced Prostate Cancer

Phase NA Withdrawn

Prostatic Neoplasms

NCT00082147 2018-06-13

Magnetic Resonance Imaging to Locate and Characterize Prostate Cancer

Phase NA Completed

20 enrolled

BreastGenitourinaryGynecologicHead & NeckSarcoma

Prostatic Neoplasms

NCT00004261 2018-02-22

EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma

Phase 1 Terminated

Breast Carcinoma In Situ, Breast Neoplasms, Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Oropharyngeal Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Inflammatory Breast Neoplasms

NCT00898326 2017-06-02

SHIP36B

198 enrolled

Prostatic Neoplasms

NCT03174054 2017-06-02

The Value of PSMA-PET Compared With Multi-parametric MRI in the Detection Prostate Lesions

Unknown

70 enrolled